As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
7 Analysts have issued a Aptose Biosciences Inc. forecast:
7 Analysts have issued a Aptose Biosciences Inc. forecast:
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -36 -36 |
28%
28%
|
|
| EBIT (Operating Income) EBIT | -36 -36 |
29%
29%
|
|
| Net Profit | -36 -36 |
27%
27%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
| Head office | Canada |
| CEO | William Rice |
| Founded | 1986 |
| Website | aptose.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


